Healthcare Industry News: BioMarin Pharmaceutical
News Release - February 20, 2007
Bio-Rad Announces the Appointment of New Board MemberHERCULES, CA--(Healthcare Sales & Marketing Network)--Feb 20, 2007 -- Bio-Rad Laboratories, Inc. (AMEX:BIO ) and (AMEX:BIO-B ), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that Louis Drapeau has been appointed to its Board of Directors and will serve as a member of the Board's Audit Committee. He replaces Philip L. Padou who passed away late last year.
Mr. Drapeau currently serves as Chief Financial Officer and Senior Vice President of Finance at Nektar Therapeutics. Previously, Mr. Drapeau has served in several executive positions including Acting Chief Executive Officer as well as Senior Vice President and Chief Financial Officer at BioMarin Pharmaceutical, Inc., and Audit Partner and Managing Partner of Northern California Audit and Business Consulting at Arthur Andersen. He currently serves on the Board of Directors of Inflazyme Pharmaceuticals Ltd. where he is the Chair of the Board's Audit Committee. Mr. Drapeau holds a Bachelor of Science degree in Mechanical Engineering and a Master of Business Administration from Stanford University.
Bio-Rad Laboratories, Inc. (AMEX:BIO ) and (AMEX:BIO-B ) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of $1.1 billion in 2005. For more information, visit www.bio-rad.com.
Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.
Source: Bio-Rad Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.